A Study on Antiviral Treatment of Chronic Hepatitis B in Children

NCT05792761 | Unknown

• 1 other identifier: Sprout project
• Study Type: interventional
• Target: 1,900
• Locations: 1 country
• Sites: 1

Brief Summary

There are nearly 2 million HBsAg-positive children who are in urgent need of professional diagnosis and treatment in China. Chronic hepatitis B (CHB) is the leading cause of childhood liver disease. After infected with HBV virus, some children will develop disease progression, and some even develop cirrhosis and/or liver cancer. In pediatric liver cancer cases, up to 34% \~ 95% are caused by HBV infection. Although two major classes of drugs have been approved for the treatment of chronic hepatitis B in adults, and there are multiple guidelines worldwide for the management of HBV infection in adults, there is lack of guidelines specifically for the management of children with HBV infection. In addition, the treatment of chronic hepatitis B in children faced great difficulties due to the lack of evidence-based medical evidence for antiviral treatment of chronic hepatitis B in children and fewer drugs approved for anti-HBV treatment in children. The timing of treatment, medications, and clinical management strategies are all controversial. This study ( Sprout project)，is a multicenter, prospective, cohort study in China, aiming to explore and optimize the antiviral treatment regimen for children with HBV infection, to provide evidence-based medical for antiviral treatment, and to provide basis evidence for the standardized management of children infection with HBV in China. The study is expected to enroll 1900 pediatric patients with HBV infection, and patient will received one of the three following treatment Strategies: nucleoside monotherapy, peginterferon α- combined with nucleoside therapy, or peginterferon α-pulse therapy combined with nucleoside therapy, according to their illness state and desire, and the safety and efficacy will be evaluated.

Conditions

Chronic HBV Infection

Outcome Measures

Primary Outcomes (1)

• Clinical cure rate.

  Defined as the proportion of child patients with HBsAg \< 0.05 IU / mL (or below the lower detection limit) 24 weeks after completing treatment, HBeAg negative, HBV DNA undetectable, and normalization of liver biochemical indexes (ALT and AST).

  24 weeks after completing treatment.

Secondary Outcomes (11)

• Proportion of patients with HBV-DNA negative in those with HBV-DNA positive at baseline.

  24 weeks after treatment completion

• HBeAg seroconversion rate in HBeAg positive children.

  24 weeks after treatment completion.

• HBsAg seroconversion rate.

  24 weeks after treatment completion.

• ALT normalization rate.

  48 weeks and 96 weeks after starting treatment

• Decrease of HBV-DNA compared to baseline.

  24 weeks after treatment completion.

Study Arms (3)

treatment-naïve children with hepatitis B

EXPERIMENTAL

Drug: Peginterferon alfa-2b combined and ETV

previously treated children with hepatitis B

EXPERIMENTAL

Drug: Peginterferon alfa-2b combined and ETV

chronic HBV carrying children with normal ALT

EXPERIMENTAL

Drug: Peginterferon alfa-2b combined and ETV

Interventions

Peginterferon alfa-2b combined and ETV DRUG

Child patients are assigned to one of the 3 treatment regimens according to their illness state and treatment desire of their parents/guardians, and the number of patients in each group is expected to limited to 300. 1. NA monotherapy group : received entecavir (ETV) for 96 weeks. 2. Combination therapy group: received peginterferon alfa-2b combined with ETV for 96 weeks. 3. Pulse therapy group :received peginterferon alfa-2b pulse treatment combined with ETV for 144 weeks.

chronic HBV carrying children with normal ALT; previously treated children with hepatitis B; treatment-naïve children with hepatitis B

Eligibility Criteria

• Age: 3 Years - 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Aged 3 to 18 (included 3 years old, but exclude 18 years old);
• HBV DNA positive (higher than the lower detection limit or \>20 IU/ml. Roche reagent is recommended).
• HBsAg positive (higher than lower detection limit or \>0.05 IU/ml. Roche reagent is recommended).
• ALT flares between 1 to10 ULN at least twice a year. If the last examination result is higher than 5ULN, the investigator shall comprehensively judge whether the child patient is suitable to participate in this study.
• The guardian should understand and sign the informed consent form (if parents is the legal guardians, they both must sign the informed consent form). Children older than 8 years (included) also must sign the informed consent form. The consent comment of child patient under the age of 8 should also be clearly recorded.
• Aged 3 to 18 (included 3 years old, but exclude 18 years old);
• Previously received NA treatment for ≥ 1 year.
• HBsAg positive (higher than lower detection limit or \>0.05 IU/ml. Roche reagent is recommended).
• The guardian should understand and sign the informed consent form (if parents is the legal guardians, they both must sign the informed consent form). Children older than 8 years (included) also must sign the informed consent form. The consent comment of child patient under the age of 8 should also be clearly recorded.
• Aged 3 to 18 (included 3 years old, but exclude 18 years old);
• HBV DNA positive (higher than lower detection limit or \>20 IU/ml. Roche reagent is recommended).
• HBsAg positive (higher than lower detection limit or \>0.05 IU/ml. Roche reagent is recommended).
• Serum ALT and AST remain persistently normal (2 consecutive follow-up visits within half a year, with an interval of at least 3 months)
• TThe guardian should understand and sign the informed consent form (if parents is the legal guardians, they both must sign the informed consent form). Children older than 8 years (included) also must sign the informed consent form. The consent comment of child patient under the age of 8 should also be clearly recorded.

You may not qualify if:

• Co-infected with HAV, HCV, HDV, HEV or HIV.
• Patients with contraindications to peginterferon alfa-2b, including but not limit to :
• Hepatitis B cirrhosis decompensated stage.
• Child patient with autoimmune liver disease, metabolic liver disease or alcoholic liver disease; malignant tumor, decompensated liver disease, or organ transplantation.
• Child patient with severe neurological or mental disorders.
• Child patient with severe hyperthyroidism or other autoimmune disorders.
• Child patient with diabetes under poorly controlled.
• Child patient with retinal or fundus lesions.
• Child patient with severe heart disease, coronary heart disease or cerebrovascular disease.
• Child patient with poorly controlled epilepsy.
• Child patient with severe renal dysfunction, e.g. creatinine \> 1.5 ULN.
• Child patient who in the opinion of the investigator is unsuitable for enrollment.

Sponsors & Collaborators

• Fang Wang: lead

Study Sites (1)

Shenzhen Third People Hospital

Shenzhen, China

RECRUITING

MeSH Terms

Interventions

entecavir

Study Officials

• Qing He

  Shenzhen Third People's Hospital

  PRINCIPAL INVESTIGATOR

• Hongfei Zhang

  Beijing Tsinghua Changgeng Hospital

  PRINCIPAL INVESTIGATOR

• Fang Wang

  Shenzhen Third People's Hospital

  STUDY CHAIR

Central Study Contacts

Fang Wang

CONTACT

+8613682662543; kaixin919@163.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Chief physician

Study Record Dates

• First Submitted: February 23, 2023
• First Posted: March 31, 2023
• Study Start: May 6, 2021
• Primary Completion: December 31, 2025
• Study Completion: December 31, 2025
• Last Updated: March 31, 2023

Record last verified: 2023-03

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)